Showing results (81-90 of 121) with videos related to
Sort By:
Pageof 13
Diabetology & Metabolic Syndrome|March 1, 2016
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trialYaeko Kondo, Norio Harada, Akihiro Hamasaki, et al.Ebiomedicine|May 23, 2022
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a studyKiminori Kimura, Tatsuya Kanto, Shinji Shimoda, et al.International Urology and Nephrology|March 18, 2016
The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS)Motohiro Shimizu, Norihiro Furusyo, Yuuki Tanaka, et al.Journal of Gastroenterology and Hepatology|August 9, 2025
Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal ImpairmentEiichi Ogawa, Motoyuki Kohjima, Toshimasa Koyanagi, et al.Journal of Gastroenterology and Hepatology|February 3, 2025
Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting AntiviralsEiichi Ogawa, Akira Kawano, Motoyuki Kohjima, et al.The Journal of Infectious Diseases|June 26, 2020
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting AntiviralsEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.Cancers|September 16, 2020
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis CEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.Journal of Gastroenterology and Hepatology|October 7, 2021
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infectionEiichi Ogawa, Akira Kawano, Aritsune Ooho, et al.Alimentary Pharmacology & Therapeutics|June 23, 2022
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort studyEiichi Ogawa, Makoto Nakamuta, Toshimasa Koyanagi, et al.Hepatology International|January 25, 2022
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort studyEiichi Ogawa, Makoto Nakamuta, Toshimasa Koyanagi, et al.Pageof 13